Amine derivatives and pharmaceutical compositions containing them
AssigneeGlaxo Group Limited
InventorsMichael Martin-Smith, Barry J. Price, John Bradshaw, John W. Clitherow
Life of this patent
Estimating the term…
Loading patent…
AssigneeGlaxo Group Limited
InventorsMichael Martin-Smith, Barry J. Price, John Bradshaw, John W. Clitherow
Estimating the term…
The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, N-oxides, hydrates and bioprecursors thereof, in which Y represents .dbd.O, .dbd.S, .dbd.CHNO.sub.2 or .dbd.NR.sub.3 where R.sub.3 represents hydrogen, nitro, cyano, lower alkyl, aryl, lower alkylsulphonyl or arylsulphonyl; R.sub.1 and R.sub.2, which may be the same or different, each represent hydrogen lower alkyl, cycloalkyl, lower alkenyl, aralkyl, hydroxy, lower trifluoroalkyl, lower alkyl substituted by hydroxy, lower alkoxy, amine, lower alkylamino or dialkylamino, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring which may contain other heteroatoms or the group ##STR2## where R.sub.4 represents hydrogen or lower alkyl; Q represents a furan or thiophen ring in which incorporation into the rest of the molecule is through bonds at the 2- and 5-positions, or a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions; X represents --CH.sub.2, --O-- or --S--; n represents zero, 1 or 2; m represents 2, 3 or 4; Alk represents a straight chain alkylene group of 1 to 3 carbon atoms; (except that n is not zero when X is oxygen and Q is a furan or thiophen ring system) q represents 2, 3 or 4 or can additionally represent zero or 1 when E is a --CH.sub.2 -group; p represents zero, 1 or 2; E represents --CH.sub.2 --, --O-- or --S--; and Z represents a monocyclic 5 or 6 membered carbocyclic or heterocyclic aromatic ring which may be optionally substituted by one or more groups or Z represents the group ##STR3## where Q' represents any of the rings defined for Q; Alk' represents any of the groups defined for Alk; and R.sub.5 and R.sub.6, which may be the same or different, each represent any of the groups defined for R.sub.1 and R.sub.2 ; (except that p is not zero when E is oxygen and Q' or Z is a furan or thiophen ring system). The compounds of formula (I) show pharmacological activity as selective histamine H.sub.2 -antagonists.
A compound of the formula (I) ##STR38## or a physiologically acceptable salt, N-oxide or hydrate thereof, in which Y represents .dbd.O, .dbd.S, .dbd.CHNO.sub.2 or .dbd.NR.sub.3 where R.sub.3 represents hydrogen, nitro, cyano, lower alkyl, aryl, lower alkyl sulphonyl or aryl sulphonyl;
A compound of the formula (II) ##STR40## or a physiologically acceptable salt, N-oxide or hydrate thereof, in which Y represents .dbd.O, .dbd.S, .dbd.CHNO.sub.2 or .dbd.NR.sub.3 where R.sub.3 represents hydrogen, nitro, cyano, lower alkyl, aryl, lower alkylsulphonyl or arylsulphonyl;
A compound of the formula (III) ##STR42## or a physiologically acceptable salt, N-oxide or hydrate thereof, in which Y represents .dbd.O, .dbd.S, .dbd.CHNO.sub.2 or =NR.sub.3 where R.sub.3 represents hydrogen, nitro, cyano, lower alkyl, aryl, lower alkylsulphonyl or arylsulphonyl;
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
No related US applications are recorded in the indexed filing history.
Iso-indoles; Hydrogenated iso-indoles: with oxygen atoms in positions 1 and 3, e.g. phthalimide
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
Radicals substituted by singly-bound oxygen or sulphur atoms: sulfur atoms
Substituted by singly bound oxygen or sulfur atoms: with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or…
Term ended 18 Dec 1998 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
This invention relates to new amine derivatives having a selective action on histamine receptors, to processes for the preparation thereof, to pharmaceutical compositions containing them, as well as to their use in therapeutics.
Certain novel amines have now been found which are selective H.sub.2 -antagonists that is they show inhibition of the secretion of gastric acid when this is stimulated via histamine receptors (Ash and Schlid--Brit. J. Pharmacol. Chemother. 1966 27, 427). Their ability to prevent the secretion of gastric juice when it is stimulated via histamine H.sub.2 -receptors can be demonstrated in the perfused rat stomach, using the method described in German Offenlegungsshcrift No. 2,734,070, modified by the use of sodium pentobarbitone (50 mg/kg) as anaesthetic instead of urethane and in conscious dogs equipped with Heidenhain pouches using the method described by Black et al--Nature 1972 236, 385. The compounds also antagonise the effect of histamine on the contraction frequency of isolated guinea pig right atrium. The compounds according to the invention do not modify histamine induced contractions of isolated gastrointestinal smooth muscle which are mediated via H.sub.1 -receptors.
Compounds with histamine H.sub.2 -blocking activity may be used in the treatment of conditions where there is a hypersecretion of gastric acid e.g. in gastric and peptic ulceration, as a prophylatic meaasure in surgical procedures, and in the treatment of allergic conditions where histamine is a known mediator. Thus they may be used, either alone, or in combination with other active ingredients in the treatment of allergic and inflammatory conditions such as urticaria.
The invention is illustrated but not limited by the following Examples.
A solution of 1,1-bis(methylthio)-2-nitroethene (19.8 g) and 5-[[(2-aminoethyl)thio]methyl]-N,N-dimethyl-2-furanmethanamine (6.42 g) in dry dioxan (120 ml) was heated at 80.degree. C. for 6 hours. Oxalic acid (3.8 g) in dry dioxan (40 ml) was added and the crystalline solid which separated was filtered, washed with dioxan and dried to give the title compound (12.55 g) m.p. 140.degree.-143.degree. C.
To N,N-dimethyl-5-[[[2-[(1-methylthio-2-nitroethenyl)amino]ethyl]thio]methyl] -2-furanmethanamine oxalate, formed from 1,1-bis(methylthio)-2-nitroethene (29.7 g), 5-[[(2-aminoethyl)thio]methyl]-N,N-dimethyl-2-furanmethanamine (9.63 g) and oxalic acid (5.7 g) as previously described, was added excess 2 M aqueous potassium carbonate. The suspension was extracted with ethyl acetate and the dried extract evaporated in vacuo to yield an oil which on trituration with ether yielded the title compound (10.5 g) m.p. 71.degree. C.